Cerus Corporation: Q1 2013 Form 10-Q Summary
Business context and reporting period
Cerus Corporation develops and commercializes the INTERCEPT Blood System for pathogen reduction in platelet and plasma products. The platelet and plasma systems were marketed internationally, while the red blood cell system remained in clinical development. This quarterly report covers the three months ended March 31, 2013, compared with the three months ended March 31, 2012. The company operated in one blood-safety segment.
Financial performance and liquidity
| Metric | Q1 2013 | Q1 2012 | Change |
|---|---|---|---|
| Product revenue | $9.733 million | $8.691 million | Up 12% |
| Total revenue | $9.733 million | $8.782 million | Up 11% |
| Gross profit | $4.643 million | $3.177 million | Up $1.466 million |
| Gross margin on product revenue | 48% | 37% | Up 11 percentage points |
| Operating loss | $(4.960) million | $(4.572) million | Loss widened $0.388 million |
| Net loss | $(10.252) million | $(8.834) million | Loss widened $1.418 million |
| Net loss per share | $(0.17) | $(0.17) | Unchanged |
| Cash used in operations | $(8.352) million | $(3.904) million | Use increased $4.448 million |
Product revenue growth was driven primarily by higher illuminator sales to distributors in Europe, the Commonwealth of Independent States and the Middle East, as well as higher average selling prices. Government grant revenue fell to zero from $0.091 million.
Research and development expense increased 48% to $2.700 million, reflecting greater activity on the red blood cell program and U.S. regulatory submissions. Selling, general and administrative expense increased 15% to $6.853 million. Approximate operating and net margins were negative 51% and negative 105%, respectively, based on total revenue.
The company held $69.163 million of cash and cash equivalents at March 31, 2013, compared with $26.696 million at December 31, 2012. Working capital increased to $59.8 million from $18.4 million. Total debt was $6.955 million, including $4.470 million current debt and $2.485 million non-current debt; $2.828 million was outstanding under the revolving line of credit. In April 2013, the company repaid its Growth Capital Loan for approximately $4.2 million, leaving the revolving line as the principal reported borrowing.
Material changes versus the prior comparable period
- Revenue increased 11%, while cost of product revenue declined 8%, improving product gross margin from 37% to 48%.
- Operating expenses increased $1.763 million, led by research and development and selling, general and administrative spending.
- The company recorded a $5.073 million non-cash loss from revaluation of its warrant liability, compared with $4.461 million in Q1 2012. The warrant liability increased to $10.976 million from $5.903 million at December 31, 2012.
- Net cash from financing activities was $50.845 million, including approximately $38.0 million of net proceeds from a March public offering and $13.0 million from sales under the Cantor equity agreement. These financings materially increased cash but diluted existing shareholders.
- Inventory increased to $11.756 million from $10.180 million, reflecting anticipated demand and supply-chain management. Four customers represented approximately 63% of trade receivables at March 31, 2013, and three customers represented approximately 59% at year-end 2012.
- Stock-based compensation increased to $0.713 million from $0.542 million.
Guidance, outlook, risks and unusual items
Management expected product revenue for the platelet and plasma systems to increase as market acceptance expanded, but stated that historical results may not be indicative of future results. The company expected research and development spending to increase with planned red blood cell clinical work and modular FDA submissions for plasma and platelet systems. It did not expect government grant revenue in the foreseeable future.
The FDA approved the proposed modular PMA shell for the plasma system in March 2013. The FDA also indicated that existing clinical and European haemovigilance data could support a proposed modular PMA submission for the platelet system without additional Phase III trials at that time, although post-marketing studies would be required. Approval remained uncertain and could require additional studies, expense or funding.
Management believed cash from product sales, available cash and debt access would fund requirements for at least the next twelve months, but acknowledged that additional capital would be required for red blood cell development and potentially other clinical or regulatory activities. The company expected continuing losses and might need additional equity, debt, grants or partnering financing. Equity financing could materially dilute shareholders.
Key risks included limited market adoption and reimbursement, lack of U.S. approvals, regulatory and clinical delays, reliance on Fresenius and other sole-source suppliers, manufacturing defects and product recalls, inventory obsolescence, customer and distributor concentration, foreign-exchange exposure, intellectual-property disputes, product liability, competition, and the need to comply with debt covenants. During the quarter, certain Fresenius-manufactured plasma processing sets were affected by defective valves; Fresenius accepted responsibility for re-inspection and remediation, and the company had not sold the affected inventory.
Important facts for investors to verify
- Whether product revenue growth and the 48% gross margin were sustained after the quarter and were not primarily driven by unusual illuminator or distributor sales.
- The timing, cost and regulatory status of the modular FDA submissions for the plasma and platelet systems.
- The cash runway after the April 2013 repayment of approximately $4.2 million and continuing operating cash use of $8.4 million in Q1.
- Future financing needs, equity dilution and the remaining availability under the Cantor equity agreement.
- The outstanding revolving credit balance, covenant compliance and repayment requirements due in 2014.
- Resolution of Fresenius-related defective inventory and warranty claims, including the remaining $0.3 million warranty claim at March 31, 2013.
- Customer, distributor and geographic concentration, particularly the three customers representing 51% of Q1 product revenue.
- Whether the company can achieve broad commercial adoption and eventually reach positive operating cash flow; the filing provides no specific profitability date or formal revenue guidance.